Using RWE to Inform the Value and Affordability Assessment of Cell and Gene Therapies

Go Back

Many CGTs have the potential to offer transformative benefits for patients. However, at launch there is often resistance from payers to reimburse these therapies due to limitations in the supporting evidence (small, single arm trials, etc). This causes uncertainty as to their value and affordability. This course will explore how real-world evidence can address critical areas uncertainty.